Zobrazeno 31 - 40
of 131
pro vyhledávání: ''
Autor:
Kyle B. Lupo, Sandro Matosevic
Publikováno v:
Journal of Hematology & Oncology, Vol 13, Iss 1, Pp 1-10 (2020)
Journal of Hematology & Oncology
Journal of Hematology & Oncology
Natural killer (NK) cells are powerful immune effectors, modulating their anti-tumor function through a balance activating and inhibitor ligands on their cell surface. Though still emerging, cancer immunotherapies utilizing NK cells are proving promi
Autor:
Lingyun Ye, Wei Li, Yayi He, Yu Liu, Hao Wang, Sha Zhao, Peixin Chen, Minlin Jiang, Bin Chen, Caicun Zhou, Lei Wang
Publikováno v:
Journal of Hematology & Oncology, Vol 13, Iss 1, Pp 1-11 (2020)
Journal of Hematology & Oncology
Journal of Hematology & Oncology
Cytosolic DNA sensing, the cyclic GMP-AMP synthase-stimulator of interferon genes (cGAS-STING) pathway, is an important novel role in the immune system. Multiple STING agonists were developed for cancer therapy study with great results achieved in pr
Autor:
Jie Chen, Zhidi Pan, Yueqing Xie, Yuexian Zhou, Lei Han, Baohong Zhang, John Gilly, Rui Sun, Huifang Zong, Jianwei Zhu, Huili Lu, Hua Jiang
Publikováno v:
Journal of Experimental & Clinical Cancer Research, Vol 39, Iss 1, Pp 1-14 (2020)
Journal of Experimental & Clinical Cancer Research : CR
Journal of Experimental & Clinical Cancer Research : CR
Background Prolactin receptor (PRLR) is highly expressed in a subset of human breast cancer and prostate cancer, which makes it a potential target for cancer treatment. In clinical trials, the blockade of PRLR was shown to be safe but with poor effic
Publikováno v:
Journal of Hematology & Oncology, Vol 13, Iss 1, Pp 1-15 (2020)
Journal of Hematology & Oncology
Journal of Hematology & Oncology
Cancer immunotherapy has reached a critical point, now that immune checkpoint inhibitors and two CAR-T products have received market approval in treating 16 types of cancers and 1 tissue-agnostic cancer indication. Accompanying these advances, the 20
Publikováno v:
Molecular Cancer, Vol 19, Iss 1, Pp 1-16 (2020)
Molecular Cancer
Molecular Cancer
Epigenetics is dynamic and heritable modifications to the genome that occur independently of DNA sequence. It requires interactions cohesively with various enzymes and other molecular components. Aberrant epigenetic alterations can lead to inappropri
Publikováno v:
Molecular Cancer, Vol 19, Iss 1, Pp 1-12 (2020)
Molecular Cancer
Molecular Cancer
It is well acknowledged that immune system is deeply involved in cancer initiation and progression, and can exert both pro-tumorigenic and anti-tumorigenic effects, depending on specific microenvironment. With the better understanding of cancer-assoc
Publikováno v:
Molecular Cancer, Vol 19, Iss 1, Pp 1-16 (2020)
Molecular Cancer
Molecular Cancer
Circular RNAs (circRNAs), one type of non-coding RNA, were initially misinterpreted as nonfunctional products of pre-mRNA mis-splicing. Currently, circRNAs have been proven to manipulate the functions of diverse molecules, including non-coding RNAs,
Autor:
Weibin Wang, Jinshou Yang, Cheng Qin, Guangyu Chen, Gang Yang, Yupei Zhao, Fangyu Zhao, Huanyu Wang, Bo Ren, Lei You
Publikováno v:
Molecular Cancer, Vol 19, Iss 1, Pp 1-19 (2020)
Molecular Cancer
Molecular Cancer
Pancreatic cancer is currently one of the most lethal diseases. In recent years, increasing evidence has shown that reprogrammed metabolism may play a critical role in the carcinogenesis, progression, treatment and prognosis of pancreatic cancer. Aff
Autor:
Miao Xu, Wenming Cui, Hui Yang, Yongquan Feng, Xuewei Chen, Qiannan Zhang, Lei Wang, Yongning Li, Xin Zhang, Xudong Jia
Publikováno v:
Molecular Cancer, Vol 19, Iss 1, Pp 1-14 (2020)
Molecular Cancer
Molecular Cancer
Background The poor prognosis of esophageal squamous cell carcinoma (ESCC) highlights the need for novel strategies against this disease. Our previous study suggested the involvement of CCL2 and tumor associated macrophages (TAMs) in esophageal carci
Circulating tumor cells in cancer patients: developments and clinical applications for immunotherapy
Autor:
Hangtian Zhang, Yifan Jia, Tian He, Xiaoming Zhong, Jing Li, Cheng Wang, Yu Sun, Hui Zhang, Zunfu Ke, Jiachen Li, Ying Zhu, Yuqing Liang, Zhuolin Yuan, Jiangyuan Zhu, Xin Li, Wengting Jiang
Publikováno v:
Molecular Cancer, Vol 19, Iss 1, Pp 1-12 (2020)
Molecular Cancer
Molecular Cancer
Cancer metastasis is the leading cause of cancer-related death. Circulating tumor cells (CTCs) are shed into the bloodstream from either primary or metastatic tumors during an intermediate stage of metastasis. In recent years, immunotherapy has also